Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ALDA Pharmaceuticals' patent application describing the composition, production methods and certain therapeutic uses for T36 formulation has been approved by the Canadian Intellectual Property Office (CIPO).
Subscribe to our email newsletter
The company has submitted another patent application covering protection for the T36 formula in combination with anesthetics, analgesics and anti-inflammatories as a treatment for a range of topical infections in the US and the EU.
ALDA pharma has already received two patents from the US and Australian regulatory agencies.
The T36 formulation has obtained one patent in China and another is pending in both China and the EU.